SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY.

MicroCloud Hologram Inc

MicroCloud Hologram ($HOLO) is trending as traders discuss a potential short squeeze, fueled by news of quantum computing advancements and Bitcoin investments. The stock's history of volatility and past rallies are driving speculation around quick gains, with some comparing it to the $GME surge. Community members are actively weighing price targets and the potential for another multi-day run.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following news of its partnership with Red Lobster to implement AI-powered phone ordering across all locations, a deal hailed as a significant client win. The community speculates on potential future partnerships with major chains like McDonald's, anticipating substantial growth for SOUN. Traders are closely watching for a potential short squeeze, with many expressing bullish sentiment and expecting new all-time highs.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is trending after announcing a partnership with NTT Innovative Devices to develop optical engines for AI-driven mobile networks, potentially disrupting the mobile network industry. The community views this as a significant step, anticipating prototypes by 2026 and high-volume production in 2027. This news reinforces POET's position in the AI and connectivity sectors.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending due to its partnership with SMX to enhance maritime awareness for the U.S. Navy, generating excitement around the company's role in applying AI to defense. Community discussions focus on the potential for a short squeeze and the stock's ability to break through resistance levels, with some drawing comparisons to Palantir and highlighting the significance of government contracts in the AI space.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony (UAMY) is trending following news of a $245 million sole-source contract from the U.S. Defense Logistics Agency for antimony ingots, sparking excitement among investors. The community views this as a major win for the company, potentially leading to significant revenue growth and solidifying its position as a key domestic supplier of a critical mineral. Some are drawing comparisons to other companies that have benefited from government contracts in the sector.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN.X is trending as the community rallies around its vision of merging cannabis culture with decentralized finance. разговоры are centered on the coin's cultural significance and its potential within the growing cannabis industry. Many community members emphasize the importance of positivity and a shared culture, viewing WEEDCOIN.X as more than just a meme token.

Super League Enterprise, Inc. creates innovative and immersive entertainment experiences, platform and audience monetization and dynamic content feeding channels across the world’s top gaming platforms. Fueled by an insatiable desire to stay on the forefront of this ever-evolving meta landscape, Super League pioneer's proprietary digital solutions provide unparalleled access to the global gaming audience. It also creates vibrant in-game communities through the development of innovative experiences and custom content, delivering powerful opportunities for brands and advertisers to achieve impactful insights, and marketing outcomes with audiences of all ages. The company was founded by John C. Miller, David Steigelfest, and Brett Morris on October 1, 2014 and is headquartered in Santa Monica, CA.

Super League Enterprise Inc

Super League Enterprise is trending as traders discuss potential breakouts and high borrow fees attracting short sellers. The community is weighing the impact of a recently announced strategic equity investment and its potential to address Nasdaq compliance. Discussions also revolve around possible dilution from new shares and warrants, with some anticipating volatility and a multi-day run.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is trending as the community discusses its potential in the autonomous trucking market, highlighting recent progress in driverless operations and expansion into new locations. Community members are pointing to institutional investment, insider buying, and potential legislative tailwinds as reasons for optimism. The stock is also seeing increased attention due to its presence in discussions about AI and autonomous vehicle technology.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to recent analyst upgrades and anticipation surrounding its inclusion in the S&P 500, with the community actively debating its potential role in a TikTok deal and its continued upward trajectory. Discussions revolve around whether the stock is overvalued, with some anticipating a pullback after the S&P 500 inclusion, while others foresee further gains. Bullish sentiment is fueled by the company's growth prospects and potential market share gains.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as the community discusses potential bullish signals, including inverted head and shoulders patterns and high short interest that could lead to a squeeze. Optimism is fueled by overnight price action and anticipation of surpassing the $10 mark, while some caution against bearish signals and choppy trading. Discussions also involve the broader eVTOL sector and comparisons to competitors like Joby Aviation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

United States Antimony Corp. (UAMY) reportedly said on Tuesday it has secured a five-year contract worth up to $245 million from the U.S. Defense Logistics Agency.According to a Reuters report, the company secured a sole-source contract to supply antimony metal ingots for the defense stockpile.Retail sentiment on the <a href="https://stocktwits.com/symbol/UAMY">stock</a> remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits. Shares of the company jumped over 21% in early trading on Tuesday.Since taking office, U.S. President Donald Trump has implemented multiple executive and policy measures to strengthen U.S. access to critical minerals as part of the country’s efforts to maintain national security and economic self-reliance. Reuters noted that Antimony, which is used in munitions, batteries, and military-grade compounds, was flagged as a vulnerability in the U.S. industrial base by defense officials.“It’s incredibly meaningful for all our employees to play such a strategic role in strengthening our nation's defense readiness," USAC CEO Gary C. Evans said, according to Reuters.The report noted that U.S. Antimony Corp operates North America’s only two antimony smelters and is positioned to begin immediate fulfillment from its domestic facilities. Reuters, citing the company, said that the first delivery order is expected this week.Shares of the company have jumped 322% this year and gained nearly 860% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-faces-ftc-in-trial-over-alleged-prime-enrollment/chDhMWHR357">Amazon Faces FTC In Trial Over Alleged Prime Enrollment Strategy: Report</a>

US Antimony Secures $245M Defense Contract Over Five Years: Report

According to a Reuters report, the company secured a sole-source contract to supply antimony metal ingots for the defense stockpile.

Equity

Strength Seen in Centrus Energy (LEU): Can Its 12.1% Jump Turn into More Strength?

Centrus Energy (LEU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Coeur Mining (CDE): Can Its 7.0% Jump Turn into More Strength?

Coeur Mining (CDE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The broader market experienced mixed performance on Monday, with major indices showing volatility but ultimately closing higher. The Dow Jones Industrial Average gained 0.78%. The S&amp;P 500 rose 0.79%, and the Nasdaq Composite climbed 0.64%. However, all three major averages were in the red at one point during the trading session. Despite this, the stocks making moves on market news continued to captivate investors with their dynamic performances and strategic advancements. In this article, we will take a look at the 6 best stocks that were making moves on market news with their groundbreaking innovations and strategic advancements.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/quantum-biopharma-expands-reach-with-new-unbuzzd-launch-and-cutting-edge-ms-clinical-study/">This Low-Float Biotech Stock is making waves with an advanced MS diagnostic tool</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>1. Recursion Pharmaceuticals (RXRX)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.34 Billion&nbsp;&nbsp;Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company that leverages artificial intelligence and automation to discover and develop novel therapeutics across a wide range of diseases.First Patient Dosed: Recursion Pharmaceuticals has recently announced the dosing of the first patient in its early-stage study of REC-3565 for treating relapsed or refractory B-cell lymphomas, which marks a significant clinical milestone.Unique Mechanism: REC-3565 has a unique mechanism of action that reduces the risk of drug-drug interactions and hyperbilirubinemia, making it potentially safer and more effective.Preclinical Success: Preclinical studies showed durable tumor regressions with REC-3565, both as monotherapy and in combination with a BTK inhibitor, which indicates strong clinical efficacy.Industry Collaborations: The company has partnerships with major pharmaceutical companies such as Roche, Bayer, Merck, and Sanofi, which provides it with additional resources and market access.FDA Policy Shift: The FDA has also announced to phase out some animal testing requirements for monoclonal antibodies, which benefits RXRX’s AI-driven platform.Stock Performance:Recursion Pharmaceuticals has shown strong weekly performance with a 45.26% gain. However, it has underperformed in the month and year, with declines of 15.69% and 31.43%, respectively.<h3>2. Certara (CERT)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.29 Billion&nbsp;&nbsp;Certara (NASDAQ: CERT) provides biosimulation software and technology-driven solutions to improve the drug development process, helping biopharma companies optimize clinical outcomes.Strong First Quarter Financial Results: On April 14, Certara reported preliminary first-quarter 2025 financial results.&nbsp; The company reported a 10% revenue growth to $106.0 million compared to the first quarter of 2024, with software revenue growing by 18% to $46.4 million.Bookings Growth: The company’s bookings increased by 12% to $118 million, with software bookings growing by 22% to 40.6 million.Adjusted EBITDA Growth: Adjusted EBITDA is expected to be in the range of $33 million to $35 million, representing a 13-20% growth compared to the first quarter of 2024.Reiteration of Full-Year Guidance: Certara reiterated its full-year 2025 guidance, projecting revenue in the range of $415 million to 425 million, an adjusted EBITDA margin of 30-32%, and adjusted diluted earnings per share of 42 to 46 cents.Stock Repurchase Authorization: The Board of Directors authorized a stock repurchase program of up to $100 million, reflecting confidence in the company’s strategy and financial performance.Non-Animal Navigator Launch: Certara launched its Non-Animal Navigator solution to help biopharmaceutical companies reduce reliance on animal testing by offering strategic regulatory advice, integrated preclinical development plans, and optimized AI-enabled modeling tools.Industry Adoption: The growing industry adoption of new approach methodologies (NAMs) like AI-enabled biosimulation supports Certara’s strategic focus and enhances its competitive position.Stock Performance:Certara has had a robust week with a 57.18% increase. However, it has faced losses over longer periods, including a 19.50% decline in performance year-to-date.<h3>3. United States Antimony (UAMY)&nbsp;&nbsp;</h3>Market Cap as of April 15: $377.72 Million&nbsp;&nbsp;United States Antimony (NYSEAMERICAN: UAMY) is involved in the mining, production, and sale of antimony and zeolite products, which are used in flame retardants, batteries, and chemical applications.Lease/Option Purchase Agreement: United States Antimony has executed a new lease/option purchase agreement with an experienced prospector in Wasilla, Alaska, for lands adjacent to existing leased and staked claims, with new claims and leases totaling 17,900 acres in the Fairbanks area and 3,840 acres near Stibnite Creek.Exploration Focus: Plans to begin high-grade stibnite exploration and mining operations in early May in the Fairbanks area. Management aims to extract antimony ore from its own mining claims in Alaska to Montana by Q3 2025.Antimony Production and Global Supply: China is the world’s top producer of antimony, but its output has been declining over the past decade, making it difficult to meet global needs without new sources. Furthermore, Antimony prices have surged due to China’s export ban, which began in December 2024.Montana Smelters: The company operates two smelters in Montana with capacities of 3,840tpa and 2,400tpa for antimony processing.Stock Performance:United States Antimony has demonstrated exceptional growth across various periods, including a strong weekly gain of 66.92%. It has also seen a remarkable year-over-year growth of 1,239.51%.&nbsp;Read Now: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/tech/u-power-makes-waves-at-bangkok-motor-show-with-groundbreaking-battery-swap-demo/">Electric Vehicle Player Is Making Waves With Groundbreaking Battery Swapping Technology</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>4. Janover (JNVR)&nbsp;&nbsp;</h3>Market Cap as of April 15: $106.54 Million&nbsp;&nbsp;Janover (NASDAQ: JNVR) provides online platforms for commercial real estate and small business loans, connecting borrowers with lenders using data-driven digital solutions.New Treasury Strategy: Janover announced a new treasury policy on April 4, 2025, to accumulate crypto assets, starting with Solana (SOL). This strategy aligns with the company’s goal of providing investors economic exposure to SOL.Significant SOL Purchases: Janover made substantial purchases of Solana (SOL) tokens, totaling $21.2 million across three transactions. These purchases have brought the company’s total SOL holdings to 163,651.7.Staking and Revenue Generation: The company will begin staking its SOL position immediately, generating revenue while supporting the Solana network. Staking rewards are also planned to be reinvested, which will further enhance cryptoasset holdings.Recent Financing Round: Janover has also raised $42 million in a financing round from investors including Pantera Capital and Kraken. These funds are specifically allocated for acquiring digital assets.Stock Performance:Janover has seen explosive growth, with a week-over-week performance of 130.20% and a remarkable 1707.42% increase in the month.<h3>5. Skye Bioscience (SKYE)</h3>Market Cap as of April 15: $82.40 MillionSkye Bioscience (NASDAQ: SKYE) is a pharmaceutical company focused on developing cannabinoid-derived molecules to treat glaucoma and other diseases with unmet medical needs.Significant Weight Loss in Preclinical Study: On April 15, Skye Bioscience announced over 30% weight loss in a diet-induced obesity model when nimacimab was combined with tirzepatide, which showcases its strong efficacy and potential as a combination therapy.Comparable Efficacy to Monlunabant and Tirzepatide: Nimacimab alone achieved 23.5% weight loss, comparable to other leading obesity drugs like tirzepatide and monlunabant, which indicates robust monotherapy potential.Differentiated Mechanism: Nimacimab’s non-competitive allosteric binding to the CB1 receptor provides a differentiated mechanism compared to monlunabant and has potentially fewer neuropsychiatric side effects.Superior Potency in High Agonist Conditions: In vitro data showed nimacimab’s potency remained stable under high agonist conditions, while monlunabant’s effectiveness was significantly impacted, which indicates superior performance in disease states like obesity.Phase 2a Data: Top-line data from the Phase 2a CBeyond study is expected in late Q3/early Q4 2025, which will provide investors with near-term clinical validation of nimacimab’s efficacy.Focus on Metabolic Health: Skye’s focus on developing next-generation molecules for metabolic health disorders aligns with the growing demand for effective obesity treatments in the market.First-In-Class Therapeutic Potential: Nimacimab’s mechanism of action as a negative allosteric modulating antibody for CB1 inhibition positions it as a first-in-class therapeutic with clinical and commercial differentiation.Stock Performance:Skye Bioscience has had a mixed performance, with a significant weekly gain of 143.32% but a modest monthly gain of only 15.41%.<h3>6. Aerovate Therapeutics (AVTE)</h3>Market Cap as of April 15: $79.12 MillionAerovate Therapeutics (NASDAQ: AVTE) is a biotechnology company developing inhaled therapies for rare cardiopulmonary diseases, with a lead candidate targeting pulmonary arterial hypertension.Expected Cash Dividend: Aerovate Therapeutics expects to declare a cash dividend in the range of $67.6 million to $69.6 million in the aggregate, based on its estimated net cash immediately prior to the closing of its merger with Jade Biosciences, which was announced on October 30, 2024.Merger Status: The Merger remains subject to approval by Aerovate’s stockholders and other closing conditions. The special meeting for stockholder approval is scheduled for April 16, 2025, with the Closing expected on or about April 28, 2025.Dividend Declaration: The official declaration of the Cash Dividend is subject to approval by the Aerovate board of directors and is expected to be announced later this month.Payment Details: The dividend will be paid with an estimated $2.40 per share based on 28,985,019 shares outstanding as of April 9, 2025. The payment date is scheduled for April 29, 2025.Purpose of Merger: The merger will combine Aerovate’s expertise in rare cardiopulmonary diseases with Jade’s focus on developing best-in-class therapies for autoimmune diseases. This combination is expected to create a robust pipeline and enhanced capabilities to address critical unmet medical needs.Stock Performance:Aerovate Therapeutics has exhibited extraordinary performance, with a week-over-week gain of 2914.67% and a month-over-month gain of 2975.95%, making it a standout performer among the stocks listed.<h3>Conclusion</h3>As we conclude our review of these promising companies, it’s clear that these stocks making moves on market news are not just fleeting trends but represent substantial investment opportunities. Each company discussed here is leveraging cutting-edge technology, strategic partnerships, and market shifts to propel their businesses forward, making them standout choices for discerning investors.&nbsp; &nbsp;Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/top-4-stocks-poised-for-big-gains/">4 Stocks Poised for Big Gains Amid Major Transformations</a> &nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:Invest@WealthyVC.com">Invest@WealthyVC.com</a>.Disclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.

Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

Others

Perpetua Resources Announces Continued Cooperation with U.S. Antimony

Perpetua Resources Announces Continued Cooperation with U.S. Antimony Perpetua Resources Announces Continued Cooperation with U.S. Antimony PR Newswire BOISE, Idaho, Dec. 9, 2024 U.S. Antimony...

Shares of United States Antimony Corp (UAMY) have rallied over the past week in the wake of escalating US-China trade tensions, reaching a 52-week high on Friday, heating up retail chatter. Earlier this week, China banned the exports of rare minerals, including antimony, gallium, and germanium, to the US, a move that could potentially mean an opportunity for companies like United States Antimony. &nbsp; Antimony is a scarce commodity, and United States Antimony sees ongoing supply issues and trade restrictions and resulting worldwide antimony metal prices as an opportunity for the company. It said in a recent release that market prices of the precious metal increased from $5.31 per pound on December 31, 2023 to about $17 per pound as of November 8. Rare minerals are also widely used in the industrial sector United States Antimony recently reported its third-quarter results, which saw its revenues rise 17% to $2.421 million and its gross profit increase 65% to $426,000.&nbsp; Loss from continuing operations was $683,000 for the quarter, up from $185,000 in the same period last year. The rise was “directly related” to the company's expanded scope of operations. Retail sentiment around the stock has turned bullish. Many Stocktwits users were optimistic about the company's prospects, given the application of the rare minerals. <stembedurl>https://stocktwits.com/theleftnutt/message/595451429</stembedurl><stembedurl>https://stocktwits.com/algo888/message/595444278</stembedurl> China’s decision to ban exports appeared to be in reaction to the U.S. curbing exports to 140 companies earlier this week. United States Antimony is up 602% year-to-date. &nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail sentiment around the stock has turned bullish| Image source: WIkimedia Commons

United States Antimony Stock Rallies On Potential Opportunity From China Precious Metals Ban: Retail Bullish

Retail sentiment on the stock has turned bullish. 

U.S. Antimony (UAMY) Announces Plan to Discontinue Latin America Operational Activities

THOMPSON FALLS, MT / ACCESSWIRE / March 11, 2024 / United States Antimony Corporation ('USAC' or 'U.S. Antimony' or the 'Company'), (NYSE:UAMY) announces plan to discontinue all Latin America...

USAC Announces Appointment of Jeffrey Fink as Vice President & General Manager of Bear River Zeolite ("BRZ")

THOMPSON FALLS, MT / ACCESSWIRE / January 29, 2024 / United States Antimony Corporation ('USAC'), (NYSE:UAMY) is pleased to announce the appointment of Jeffrey Fink, age 39, as Vice President and...

$BBAI

$BETR

$OPEN

$IONQ

Which of these trending stocks are you most bullish on for the next 5 years?

Current Price	$7.82
Prev Close	$6.45
Open	$7.05
Dividend Yield	0.00%
50-Day Moving Average	$4.20
Beta	1.21
Avg. Volume	6.22M
PE Ratio	-716.67

52-Week High	$6.68
52-Week Low	$0.4901
Market Capitalization	$830.3M
EPS (Annual)	-$0.016
Price to Book	20.50
Revenue Per Employee	$240,934.87
Enterprise Value/EBITDA	N/A

UAMY
United States Antimony Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UAMY News

UAMY United States Antimony Corp